We are live on ! Find out more
SCPH

scPharmaceuticals
SCPH

Delisted

SCPH was delisted on the 6th of October, 2025.

Back to rankings

31 hedge funds and large institutions have $23.5M invested in scPharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $22.5M → $23.5M (+$1.06M)

0.61% less ownership

Funds ownership: 40.28% → 39.67% (-0.61%)

11% less funds holding

Funds holding: 35 → 31 (-4)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

54% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 13

Holders
31
Holders Change
-4
Holders Change %
-11.43%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
6
Reduced
13
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$1.28M
2
EP
Eversept Partners
New York
+$570K
3
AIM
Alambic Investment Management
California
+$196K
4
Renaissance Technologies
Renaissance Technologies
New York
+$149K
5
Millennium Management
Millennium Management
New York
+$110K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.07M
2
AIC
AWM Investment Company
New York
-$738K
3
State Street
State Street
Massachusetts
-$292K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$235K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$73.1K

SCPH Hedge Fund Activity: Q2 2019 in Review

31 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q2 2019, worth a combined $23.5M — up 4.7% from $22.5M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of SCPH and 8 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 6 added.

The largest buyer was RA Capital Management, adding an estimated $1.28M. The largest seller was BlackRock, cutting an estimated $1.07M.

  • 31 institutional investors held scPharmaceuticals (SCPH) as of Q2 2019, down from 35 in Q1 2019.
  • Funds reported $23.5M of scPharmaceuticals stock for Q2 2019, up 4.7% quarter-over-quarter.
  • 8 funds opened new scPharmaceuticals positions in Q2 2019 and 12 closed out, a net change of -4 holders.
  • The largest scPharmaceuticals buyer in Q2 2019 was RA Capital Management, an estimated $1.28M added.
  • The largest scPharmaceuticals seller in Q2 2019 was BlackRock, an estimated $1.07M sold.

Based on aggregated 13F filings for Q2 2019.